Head and neck squamous cell carcinoma (HNSCC) diagnoses constitute ∼3--5% of all cancers with an estimate of 49 000 new cases and 11 000 deaths in 2010 in the United States ([@bib27]; [@bib23]). Recent epidemiological data suggest an increasing incidence rate among younger people who are often nonsmokers and nondrinkers ([@bib33]; [@bib34]; [@bib7]; [@bib25]; [@bib28]), which are frequently attributable to human papilloma virus (HPV) infection ([@bib15]; [@bib11]; [@bib9]; [@bib16]; [@bib5]). Human papilloma virus-positive tumours are typically found in the oropharynx and have better response to treatment ([@bib14]) and better disease outcome ([@bib20]; [@bib2]). There is significant consensus that knowledge of patient HPV status will increasingly have a role in the management of this disease.

However, assessment of risk in the context of HPV infection has ongoing challenges. Perhaps chief among these is the fact that the diagnostic tests for the infection have limitations, and second, that smoking appears to degrade the favourable outcomes in patients with HPV-associated cancers for reasons that are unclear. There are two broad categories of assays for HPV. In the first category are tests for the virus itself including PCR, IHC and *in situ* hybridisation. Alternatively, HPV status can be assessed indirectly through the p16 biomarker, which is generally highly expressed in the setting of HPV infection. Detection of HPV directly suffers from a variety of limitations including both false positives and false negatives depending on the setting for reasons that have been extensively reviewed ([@bib35]; [@bib19]; [@bib38]; [@bib36]). Recently, large clinical trials have addressed the false positive concern primarily by assessing HPV only in the oropharynx, assuming that most positive tests outside the oropharynx would be false positives. The concern for false negatives has frequently been addressed with the addition of the biomarker p16, which is highly correlated with HPV infection because it is generally believed that HPV *in situ* hybridisation is less sensitive and more specific than p16 staining ([@bib4]; [@bib32]; [@bib36]). In fact, recent studies have consistently shown favourable correlation between the two biomarkers, with nearly all HPV-positive samples also staining for p16 ([@bib4]). Interestingly, however, there is also a consistent pattern of p16-positive, HPV-negative oropharynx tumours in the range of ∼20% ([@bib2]). Strikingly, however, p16-negative, HPV-positive tumours are rare. Most commonly, the p16-positive, HPV-negative case has been attributed to a failed test of HPV, such as the presence of an HPV subtype not assessed by the assay. Such an explanation fails to address the fact that p16 is frequently positive in HNSCC outside the oropharynx, where HPV infection has generally been classified as a rare event. Interestingly, p16 positivity within the oropharynx appears to be at least as good a marker of favourable outcome, independent of whether samples also stained for HPV ([@bib29]; [@bib2]). Yet outside the oropharynx, p16 has only infrequently been reported as a favourable marker ([@bib22]).

In addition to the complex story involving tumour site (oropharynx) and the biomarkers p16 and/or HPV is the fact that risk is also modified by smoking ([@bib2]). Patients with greater smoking histories appear to have their favourable outcomes significantly tempered relative to nonsmoking HPV/p16-positive oropharynx cases for reasons that are not explained by the biomarker staining alone. [@bib2] documented at least 30% chance of death at 3 years for HPV-positive patients with positive smoking histories. There is little question that HPV-positive/p16 positive nonsmoking patients have more favourable outcomes. However, in patient populations with high or modest smoking rate, it is still valuable to assess patients\' survival beyond HPV status. A biomarker that more precisely captures the biology of both smoking and tumour site, and that unifies the frequent discrepancies between HPV staining and p16 staining would be welcome. Recently, our group reported that p16 staining was prognostic in a set of young patients with HNSCC who were confirmed HPV negative by PCR and *in situ* hybridisation, ([@bib22]), leading us to question whether p16 alone could be extended to evaluate risk outside the oropharynx.

Smoking and HPV infection are two important etiologies of p16 alteration in HNSCC. In HPV-infected patients, the protein RB1 is inactivated by viral oncoprotein E7, leading to a high and nuclear localised p16 expression ([@bib1]; [@bib39]; [@bib24]; [@bib25]). In contrast, in situations where p16 is retained but altered in function by mutation or other genetic events, we may still observe modest to high p16 expression, but with abnormal cellular localisation. In many additional smoking patients, p16 can be lost via more deleterious genetic or epigenetic changes, such as homozygous deletion, nonsense mutation, or perhaps methylation and gene silencing. On the basis of these aetiologic differences, we expected to observe distinct patterns in p16 IHC staining. Similar hypotheses of p16\'s role in prognosis have been tested in other tumour types. For example, in high-grade astrocytoma, a study has shown that nucleus-located p16 is associated with better disease outcome while cytoplasmic p16 indicates worse patients\' survival ([@bib3]). In other tumour types, including endometrial cancers, melanoma and astrocytomas ([@bib12]; [@bib31]; [@bib37]; [@bib26]; [@bib17]; [@bib3]), reports also exist where p16 localisation is associated with disease outcomes. As p16 protein functions as a cell cycle inhibitor in the nucleus, we proposed that nuclear p16 staining and cytoplasmic p16 staining may have a distinct prognostic effect in HNSCC. We tested this hypothesis in a population-based patient cohort -- the Carolina Head and Neck Cancer Study (CHANCE).

Methods
=======

Study population
----------------

The CHANCE was a population-based case--control study of incident HNSCC conducted from 2002 to 2006 in 46 counties in Central and Eastern North Carolina ([@bib10]). The subcohort of 143 patients from this study who were treated at UNC (University of North Carolina at Chapel Hill) hospitals and had banked tissue available were eligible. Patients with cancers of all head and neck subsites except nasopharynx (oral cavity, oropharynx, larynx and hypopharynx) were included. Treatment decisions were recommended by the UNC Head and Neck multidisciplinary team and based on patient age, tumour extent, site, comorbidities and performance status. Clinical information was extracted from patient charts. Patients who received complete medical care at UNC were followed by retrospective review of the medical record for outcomes including relapse and death. Patients who had follow-up in local institutions outside UNC were followed by requesting medical records from the local institution or in cases where there was no return of information from the outside institution, patients deaths were queried from the Social Security Death Index and local obituaries in compliance with the CHANCE study protocols. Patients without sufficient tumour sample for p16 staining were excluded, leaving 135 patients in the analysis. An independent UNC TMA cohort was available for validation that our group has reported on previously ([@bib21]). Both studies were approved by the Institutional Review Board of the UNC.

Tissue microarray
-----------------

Tissue microarrays (TMAs) were constructed using core samples from formalin-fixed paraffin-embedded tumour blocks. Hematoxylin- and eosin-stained slides were reviewed by two pathologists (KF and WF) to confirm the original diagnosis. About 1-mm microarray blocks were constructed on a manual tissue microarrayer-1 from Beecher Instruments (Sun Prairie, WI, USA) in triplicate. Sequential 4-*μ*m sections were cut from each TMA. Sectioned slides were coated in paraffin and stored at 4 °C until staining. A second confirmatory tissue resource was also used for the current analysis the construction and results of which have been previously reported ([@bib21]). Briefly, a TMA (designated young nonsmoking oral cavity cohort (YNOCC)) was constructed in a similar manner as above that included a cohort of 42 HNSCC between the age of 18 and 39. Processing of tissue and reagents is otherwise consistent with the current methods.

p16 IHC staining
----------------

p16 IHC staining was carried out in the Bond Autostainer (Leica Microsystems Inc, Norwell, MA, USA) according to the manufacturer\'s IHC protocol. Slides were put in a 60° oven to remove excess paraffin. Slides were then placed in the autostainer and dewaxed in Bond Dewax solution (AR9222) and hydrated in Bond Wash solution (AR9590). Antigen retrieval was performed for 30 min at 100 °C in Bond-Epitope Retrieval solution 1 (pH 6.0, AR9961). Slides were then incubated with p16^INK4a^ antibody (mouse monoclonal anti-p16 antibody (MAB4133), Chemicon International Company/Millipore Corporation, Temecula, CA, USA) for 15 min. Antibody detection was performed using the Bond Polymer Refine Detection System (DS9800). Stained slides were dehydrated and coverslips added. Immunohistochemical staining was performed in the Translational Pathology Lab at UNC. After completion of IHC, slides are stored at room temperature in our laboratory and a virtual scanned copy of all TMA slides will be kept for further reference.

HPV *in situ* hybridisation
---------------------------

HPV *in situ* hybridisation was carried out in Ventana Benchmark XT autostainer. Slide deparaffinisation, conditioning, and staining with INFORM HPV III Family 16 Probe (B; Ventana Medical Systems, Tucson, AZ, USA) were performed on the autostainer according to the manufacturer\'s protocol. The probes have affinities to HPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 66. Slides were scored as positive for HPV if a punctate or diffuse pattern of signal was observed in the tumour nuclei.

p16 protein expression
----------------------

p16 expression was assessed by pathologists who were blinded as to the clinical data for the patients. The CHANCE TMA and the YNOCC TMA were read by two pathologists (KF and LT, respectively), with any indeterminate scores evaluated by a third pathologist (WF). Digital images of cells were captured (magnification × 200) using the Aperio Scanscope (Aperio Inc., Vista, CA, USA). Tissue samples previously shown to be p16 overexpressors (endometrium) were used as a positive control for intensity scoring. Each sample was given a cytoplasmic intensity score and nuclear intensity score on a scale of 0--3, with intensity scored 0 equal to no staining; 1, faint or focal cytoplasmic staining; 2, moderate, diffuse staining; and 3, intense and diffuse staining. The percentage of tumour cells with positive nuclei was determined by scoring 10 microscopic fields of 100 tumour cells each. A semiquantitative percentage score was generated for the cytoplasm and nucleus staining for each specimen, ranging from 0 to 100. The TMA was constructed with the goal to obtain three cores per patient block. Not every block had sufficient tissues and some cases resulted with only one or two cores. For samples that had multiple cores, mean intensity or percentage scores across the cores were used as the final intensity or percentage score for that sample. A composite product score was calculated by multiplying the mean intensity score and mean percentage score in the cytoplasm or nucleus. Based on a bimodal distribution of the scores in oropharynx patients (dark grey in Figure 2), a nuclear product score of 100 was used as a cutoff for nuclear staining. The 75% percentile of cytoplasmic staining (133.4) was considered to be a cutoff for cytoplasmic staining. All samples that had high nuclear (HN) staining also had high cytoplasmic staining, resulting in three categories in total. Patients with a nuclear product score ⩾100 were considered high nuclear staining (HN). Patients with a product score at or above the 75th percentile of the cytoplasmic score (133.4) were considered high cytoplasmic staining (HC) if they were not in the HN group. Patients who failed to meet criteria either for high nuclear or high cytoplasmic score were categorised in the low staining group (LS). Based on this empirical separation, the patients were divided into three groups; high nuclear, high cytoplasmic staining (HN), high cytoplasmic, low nuclear staining (HC) and low nuclear and cytoplasmic staining (LS).

Statistical analysis
--------------------

All statistical analysis was performed using the R 2.9.2 software (<http://cran.r-project.org>). Baseline characteristics of patients from each group (HN, HC and LS) were compared using Fisher\'s exact test for categorical variables and one-way analysis of variance for continuous variables. Overall survival was calculated as the time from diagnosis date to death date or the last documented follow-up date. Progression-free survival (PFS) was defined as the time from diagnosis date to the date of disease progression or the last documented follow-up date or death date from any cause. Disease progression was defined as any documented tumour progression (local or distant) as indicated in the clinical record. All observations were censored at 60 months. Survival curves were calculated using the Kaplan--Meier method and compared nonparametrically using the log-rank test. Cox proportional hazard model was used to estimate the hazard ratio between different p16 staining groups, adjusting for patient alcohol consumption status, tumour stage, tumour site and HPV staining. All statistical tests were two sided with a significance level of 0.05 and all reported confidence intervals (CIs) were constructed at a two sided 95% confidence level.

Results
=======

Patient characteristics
-----------------------

A total of 143 patients were identified during the study period, of which 135 had sufficient tumour samples for p16 staining. The median follow-up time for these patients was 6.67 years, with only five patients lost to follow-up before 5 years. The baseline characteristics for these patients were summarised in [Table 1](#tbl1){ref-type="table"}. The median age of patients at diagnosis was 57 (range 20--82). In all, 68.9% of the patients were males, which is comparable to the national average ([@bib30]). Most patients had smoking histories and/or alcohol use with only 12 (9%) never smokers and 44 (∼30%) never drinkers. Furthermore, all of the 123 smokers, except 2, had smoked ⩾10 pack years. Approximately 30% of the patients received single-modality treatment with surgery or radiation alone. Other patients received a combination of different treatment methods. In all, 16 (11.9%) patients were detected as HPV positive, of which 14 had oropharyngeal tumours and the other 2 had tumours in the oral cavity.

p16 expression
--------------

In the sample set p16 showed baseline cytoplasmic and nuclear staining in at least one of the three cores for every patient. Examples of IHC images of p16 staining are shown in [Figure 1](#fig1){ref-type="fig"}. Overall, oropharyngeal cancers and HPV-positive cancers had stronger p16 staining in both the cytoplasm and nucleus compared with tumours of other types ([Figure 2](#fig2){ref-type="fig"}). The median nuclear product score was 22 in oropharyngeal tumour samples compared with 0 in non-oropharyngeal samples (permutation test of equal density *P*-value \<0.001). The median cytoplasmic product score was 150 in oropharyngeal tumour samples compared with a median product score of 38 in non-oropharyngeal samples (permutation test of equal density *P*-value \<0.001). A total of 9 patients had high nuclear and high cytoplasmic p16 staining (HN), 25 patients had HC and 101 had low p16 staining (LS). There was no significant difference in age, gender, smoking status, T stages and clinical stages between different staining groups. However, patients with high nuclear or cytoplasmic p16 staining have more oropharyngeal tumours and earlier nodal stage (N0--N1) compared with the low p16 staining group.

HPV *in situ* hybridisation
---------------------------

[Table 2](#tbl2){ref-type="table"} summarised the distribution of tumour sites with respect to HPV positivity and smoking status. Overall, 16 of the 143 patients stained positively for HPV, with 14 of them having tumours in the oropharynx and 2 in the oral cavity. The HPV positivity rates were lower than some of the clinical trials and other university based reports ([@bib6]; [@bib14]), due to, at least in part, the very high smoking rate in our study population ([@bib8]; [@bib2]). In all, 37% (14/38) of oropharyngeal tumours were stained HPV positive in this study, comparable to previous reports such as RTOG 9003 ([@bib18]), which reported 39% HPV positive in oropharyngeal cancers. Human papilloma virus-positive staining outside oropharyngeal tumours was rare, which is consistent with the general acceptance of a low rate of HPV infection outside the oropharynx ([@bib4]). The vast majority of these HPV-positive patients were heavy smokers: 13 of the 16 HPV-infected patients had long histories of smoking, with a minimum of 18 pack years. Human papilloma virus infection has been strongly associated with both cytoplasmic and nuclear p16 positivity. All but three HPV-positive patients were categorised as having high nuclear or high cytoplasmic p16 expression.

Survival analysis
-----------------

In the full cohort, the 3-year OS was 63.0% (95% CI: 55.3%--71.7%) and the 3-year PFS rate was 54.1% (95% CI: 46.3%--63.2%). Only one death occurred in the HN group during the follow-up. In the LS group, the 3-year OS and PFS was estimated as 65.3% (95% CI: 56.7%--75.3%) and 54.5% (95% CI: 45.6%--65.1%) using the Kaplan--Meier method. The 3-year OS and PFS was estimated as 40% (95% CI: 24.7%--64.6%) and 36% (95% CI: 21.3%--60.7%), respectively, in the HC group ([Figure 3](#fig3){ref-type="fig"}). The 3-year OS and PFS in the HN group was 100% with CI not evaluable. Both OS and PFS results were significantly different between staining groups with a log-rank test *P*-values of 0.006 and 0.009, respectively. There is no significant difference in OS or PFS between the HPV-positive group and HPV-negative group (*P*=0.509 and 0.434, respectively).

Cox proportional hazard model was used to assess the relationship between each variable with OS and PFS ([Table 3](#tbl3){ref-type="table"}). p16 expression status was significantly associated with both OS and PFS. The HN group had the best OS outcome and the lowest hazard ratio compared with the other groups. Similar results were obtained for PFS, although the difference was not statistically significant. Using the HC group as a reference, the hazard ratio for OS was 0.50 (95% CI: 0.29--0.88) for the LS group and 0.10 (95% CI: 0.013--0.75) for the HN group. Similarly, the hazard ratio for PFS was 0.61 (95% CI: 0.35--1.04) in the LS group and 0.09 (95% CI: 0.012--0.67) in the HN staining group. If we consider local recurrence and distant recurrence separately, the 3-year local recurrence rates were 24% and 26.7% for the HC and LS group, respectively, and the 3-year distant recurrence rate was 16.0% and 10.9% for the HC and LS group, respectively. The HN group had no recurrence during 3 years of follow-up. When nuclear staining and cytoplasmic staining were considered separately for their association with OS or PFS, high nuclear staining was significantly associated with PFS (HR=0.13, 95% CI: 0.018--0.96) and insignificantly associated with OS (HR=0.17, 95% CI: 0.024--1.24). Cytoplasmic staining was not significantly associated with either OS or PFS. In addition to p16 staining status, T3--T4 tumour stage was significantly associated with increased risk of mortality (*P*-value=0.009). Nodal stages showed borderline significance in affecting OS (*P*-value=0.07). No variable tested except p16 expression status showed significant association with PFS.

Multivariable Cox proportional hazard model showed that p16 expression status was still significantly associated with both OS and PFS ([Table 4](#tbl4){ref-type="table"}) after adjusting for tumour site, nodal stage, tumour stage, HPV staining and drinking pattern. Both the LS group and the HN staining group had significantly lower hazard than the HC staining group. Subset analysis was carried out for oropharynx patients: after controlling for tumour stages, HPV staining and drinking status, the hazard ratio of OS for LS and HN groups are 0.40 (*P*=0.18) and 0.12 (*P*=0.06), respectively, and the hazard ratio of PFS for LS and HN groups are 0.61 (*P*=0.43) and 0.12 (*P*=0.06), respectively, using the HC group as reference. Subset analysis for other tumour sites was not conducted because of the small number of patients.

Independent confirmation in second cohort
-----------------------------------------

Using data from the YNOCC TMA, we were able to obtain p16 staining on an additional 42 samples, with 30 from the oral cavity, 6 from the oropharynx, 5 from the larynx and 1 from the hypopharynx. This is a cohort of younger patients who were diagnosed between the age of 20 and 39, with 23 males, 29 with smoking history (median pack year 14.5) and 18 with alcohol consumption history. Previously we had reported a favourable overall outcome for those patients in the cohort who were p16 positive. At that time, we had not evaluated the independent contribution of nuclear staining to outcomes. In this study, we evaluated those patients by the same product score cutoff as an independent validation. The patients were then grouped using the same criteria for this study: 14 patients were placed in the HN group, 4 patients in the HC group and 24 patients in the LS group. Although *P*-values are not statistically significant owing to the small sample size, strikingly, the HN staining group had superior PFS compared with the other two groups, with similar magnitude to our observations in the CHANCE data set. The hazard ratio of having a recurrence in the HN group and LS group are 0.38 (95% CI: 0.092--1.62) and 0.71(95% CI: 0.20--2.52) compared with the HC staining group (*P*=0.34).

Discussion
==========

The management of squamous cell carcinoma of the head and neck appears to be at a crossroads, with the possibility that the field may change long held treatment standards based on observations related to the staining for the biomarkers HPV and p16. Pivotal studies have documented significantly improved outcomes for patients staining positively for these markers, yet a closer look at how these biomarkers relate to each other has stimulated researchers to look for the mechanisms behind the beneficial outcome association. First, it is clear that mechanisms in addition to HPV infection itself are at work as evidenced by the modulation of risk caused by smoking. There is also at least circumstantial evidence that alterations of p16, independent of HPV, may convey some of the favourable prognoses seen in HNSCC patients that cannot simply be ascribed to false negative HPV assays. Evidence from tumours outside the head and neck lead us to consider nuclear localisation of p16 as a novel biomarker. In this report, the results comparing nuclear localisation of p16 to cases where p16 is excluded from the nucleus warrant further study. Furthermore, the results may help suggest a mechanistic role for this biomarker that go beyond an empiric view of p16 as a proxy for HPV of use limited to the oropharynx.

To consider p16 status (as indicated by p16 staining) as a mechanistic marker requires a review of the ways that p16 is altered in cancer. In the case of HPV, p16 overexpression is a result of expression of HPV-derived oncoproteins E6 and E7 and can functionally inactivate the p53 and pRb tumour-suppressor protein, resulting in a downregulation of p53, pRb and a strong upregulation of p16 at the molecular level ([@bib1]; [@bib39]; [@bib24]; [@bib25]). One could think of p16 expression in the context of HPV infection as a proxy for multiple genotypes that would generally be considered favourable for cancer prognosis (p53 wild type (WT), Rb WT and p16 WT). However, in the more common setting of tumours, p16 is lowly expressed, possibly by less favourable genetic or epigenetic changes, such as homozygous deletion of p16, nonsense mutation, or perhaps methylation and gene silencing. In those situations, where there are more deleterious mutations such as loss of Rb or perhaps amplification of cyclin D1 (common in HNSCC), the tumours can express high levels of p16 with no inhibition of cell cycling. In these situations, nuclear trafficking might be altered and high p16 expression might indicate particularly unfavourable cancer biology. Smoking could be the means of inactivation of genes downstream of p16 without requiring p16 loss as the disease modifying event associated with worse outcome. To evaluate such an explanation, we attempted to sequence p16 and other targets in the current sample set but were unsuccessful because of the quality of the DNA in these paraffin-embedded specimens.

To our knowledge, no previous study has investigated how different p16 expression localisation can be related to disease outcomes in HNSCC despite evidence that differential staining patterns similar to what we describe have been shown to be relevant in other tumours, including endometrial cancers, melanoma and astrocytomas ([@bib12]; [@bib31]; [@bib37]; [@bib26]; [@bib17]; [@bib3]). Most strikingly, familial melanoma studies strongly support our hypothesis because of the associated point mutations and the failure to localise p16 to the nucleus ([@bib17]). In this report, patients without the germline variant displayed a combined nuclear and cytoplasmic staining. The authors demonstrated that p16 mutations in these melanoma patients may impair the cytoplasmic--nuclear shuttling similar to BRCA1 where BRCA1 is shifted to the cytoplasm because of a mutation in nuclear localisation signals and the HN2-terminal ([@bib13]; [@bib17]; [@bib3]).

This study has limitations and suggests that further evaluation of p16 nuclear staining is warranted. Most notably, the current study is relatively small and includes a large number of smokers. Similarly, because of the retrospective nature of the current study, patients are heterogeneous in stage, site, treatment and other factors that might impact risk in ways that have not been appreciated. However, the prognostic effect of p16 localisation remained significant after controlling for these factors. The validation cohort provided extra support for our result. We do provide evidence regarding the use of p16 in nonsmokers with the YNOCC cohort, because this group does not include significant numbers of nonsmoking HPV-positive patients. However, because most HNSCC patients are still smokers despite the rising numbers of nonsmoking patients, these data are applicable to a larger portion of HNSSC patients. Finally, our cutoff for different p16 groups was based on the empirically observed distributions of p16 staining in oropharynx *vs* non-oropharynx samples. This cutoff was neither optimised nor cross-validated and cannot be directly used for clinical settings.

In conclusion, we have provided a preliminary investigation into the nuclear staining of p16 as a critical factor in the complex set of conditional biomarkers including HPV, smoking, oropharyngeal carcinomas and nonlocalised staining of p16. This biomarker, if validated, is already widely available and could potentially impact clinical care of HNSCC.
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![Representative examples of p16 immunostaining in HNSCC. IHC staining for p16 expression of HNSCC was evaluated by product scores in different cellular compartments separately. From the above left: (**A**) p16 high expression in both the nuclei and cytoplasm; (**B**) p16 low expression in both the nuclei and cytoplasm; (**C**) high nuclear expression and modest cytoplasmic staining (however, by our scoring this still qualified at the lowest end of 'high cytoplasmic\'); and (**D**) high cytoplasmic expression and low nuclear expression.](bjc2012264f1){#fig1}

![Distributions of p16 staining product scores.](bjc2012264f2){#fig2}

![Kaplan--Meier estimates of overall survival (**A**) and progression free survival (**B**) according to p16 expression in whole study population. All survival estimates were censored at 60 months. Abbreviations: HC=high cytoplasmic, low nuclear staining; HN=high nuclear, any cytoplasmic staining; LS=low nuclear, low cytoplasmic staining. '+\' censored observations.](bjc2012264f3){#fig3}

###### Patient characteristics by p16 staining

                                                                    **p16 Staining groups**                               
  --------------------------------------------------- ------------- ------------------------- ------------- ------------- ---------
  No. of patients                                     135           9                         25            101            
                                                                                                                          
  *Age*                                                                                                                   
  * *Median                                           57            56                        54            58            0.14
  * *Range                                            20--82        20--66                    34--79        24--82         
                                                                                                                          
  *Gender*                                                                                                                
  * *Male                                             93 (68.9)     8 (88.9)                  19 (76)       66 (65.3)     0.28
                                                                                                                          
  Smoking[a](#t1-fn2){ref-type="fn"}                  123 (91.1)    7 (77.8)                  22 (88)       94 (93.1)     0.16
  Mean pack years (s.d.)[a](#t1-fn2){ref-type="fn"}   39.8 (25.9)   41.4 (39.1)               38.0 (26.0)   40.0 (24.7)   0.93
  Alcohol[a](#t1-fn2){ref-type="fn"}                  91 (67.4)     6 (66.7)                  18 (72)       67 (66.3)     0.90
                                                                                                                          
  *T stage*[a](#t1-fn2){ref-type="fn"}                                                                                    
  * *T1--T2                                           65 (48.1)     4 (44.4)                  10 (40)       51 (50.5)     0.65
  * *T3--T4                                           70 (51.9)     5 (55.6)                  15 (60)       50 (49.5)      
                                                                                                                          
  *Nodal stage*[a](#t1-fn2){ref-type="fn"}                                                                                
  * *N0--N1                                           79 (58.5)     4 (44.4)                  8 (32)        67 (66.3)     0.004
  * *N2--N3                                           56 (41.5)     5 (55.6)                  17 (68)       34 (33.7)      
                                                                                                                          
  *Stage*                                                                                                                  
  * *Stage I--II                                      43 (31.9)     1 (11.1)                  5 (20)        37 (36.6)     0.12
                                                                                                                          
  *Site*                                                                                                                  
  * *Oropharynx                                       38 (28.1)     7 (77.8)                  15 (60)       16 (15.8)     \<0.001
  * *Larynx                                           35            1 (11.1)                  1 (4)         33 (2.7)       
  * *Oral cavity                                      54 (40)       1 (11.1)                  6 (24)        47 (46.5)      
  * *Hypopharynx                                      8 (5.9)       0                         3 (12)        5 (5.0)        
                                                                                                                          
  HPV positive                                        16 (11.9)     3 (33.3)                  10 (40.0)     3 (3.0)       \<0.001

Abbreviations: HC=high cytoplasmic, low nuclear staining; HN=high nuclear, any cytoplasmic staining; LS=low nuclear, low cytoplasmic staining.

Numbers do not sum to the total because of missing data.

###### p16 expression by smoking status and tumour site

  **p16 Expression**        **HN**                 **HC**                         **LS**
  -------------------- ---------------- ----------------------------- -------------------------------
  *Smokers*                                                           
  * *HPV negative       4 (1 OC, 3 OP)   14 (5 OC, 1 LA, 3 HY, 5 OP)   92 (40 OC,33 LA, 3 HY, 16 OP)
  * *HPV positive           3 (OP)                 8 (OP)                      2 (1 OC, 1OP)
                                                                                      
  *Nonsmokers*                                                        
   HPV negative             2 (OP)                  1(OC)                     6 (5 OC, 1 OP)
   HPV positive               0                    2 (OP)                        1 (1 OC)

Abbreviations: HC=high cytoplasmic, low nuclear staining; HN=high nuclear, any cytoplasmic staining; HPV=human papillomavirus; HY=hypopharynx; LA=larynx; LS=low nuclear, low cytoplasmic staining; OC=oral cavity; OP=oropharynx.

###### Univariate analyses of prognostic factors for overall or PFS

                                                      **PFS**   **OS**                                                                                             
  -------------------------------------------------- --------- --------- ----------------- ------------- ------- ------- --------- ----------------- ------------- -------
  *Age (years)*                                                                                                                                                    
   ⩾57/\<57                                            38/34    228/197  0.97              0.61--1.55    0.91    33/28   254/224   1.03              0.62--1.70    0.92
  Smoker/nonsmoker                                     66/6     385/41   1.19              0.52--2.74    0.69    56/5    433/45    1.19              0.48--2.97    0.71
  Drinking                                             53/19    270/154  1.55              0.92--2.62    0.10    45/16   305/174   1.61              0.91--2.84    0.10
                                                                                                                                                                   
  *Site*                                                                                                                                                           
   Larynx                                               18        111    1.17              0.61--2.25    0.63    14      134       1.01              0.49--2.10    0.97
   Oral cavity                                          29        166    1.27              0.71--2.29    0.42    26      179       1.40              0.74--2.64    0.30
   Hypopharynx                                           7       15.4    2.74              1.14--6.60    0.02    6       20        2.70              1.04--6.99    0.04
   Oropharynx                                           18        131    1.0 (Reference)                         15      145       1.0 (Reference)                  
                                                                                                                                                                   
  *T stage*                                                                                                                                                        
   T3--T4/T1--T2                                       42/30    202/221  1.49              0.93--2.38    0.10    39/22   220/258   2.02              1.20--3.41    0.009
                                                                                                                                                                   
  *N stage*                                                                                                                                                        
   N2--N3/N0--N1                                       31/41    165/259  1.16              0.73--1.86    0.52    30/31   177/301   1.61              0.97--2.65    0.07
                                                                                                                                                                   
  *Stage*                                                                                                                                                          
   Late(III--IV)/early(I--II)                          52/20    281/144  1.29              0.77--2.17    0.33    47/14   309/169   1.79              0.98--3.25    0.06
                                                                                                                                                                   
  *p16: Combined nuclear and cytoplasmic staining*                                                                                                                 
   HN                                                    1        45     0.09              0.012--0.67   0.067   1       45        0.10              0.013--0.75   0.025
   LS                                                   53        319    0.61              0.35--1.04    0.019   43      365       0.50              0.29--0.88    0.017
   HC                                                   18        61     1.0 (Reference)                         17      68        1.0 (Reference)                  
                                                                                                                                                                   
  *HPV*                                                                                                                                                            
   ±                                                   7/65     55/368   0.73              0.34--1.60    0.44    6/22    60/418    0.75              0.32--1.75    0.51

Abbreviations: CI=confidence interval; HC=high cytoplasmic, low nuclear staining; HN=high nuclear, high cytoplasmic staining; HR=hazard ratio; LS=low nuclear, low cytoplasmic staining; OS=overall survival; PFS=progression-free survival; PYs=person-years.

###### Multivariate analysis of prognostic factors for survival or PFS

                   **PFS**         **OS**                                            
  ---------------- --------------- ------------ ------ --------------- ------------- ------
  T3--T4/T1--T2    1.32            0.77--2.26   0.31   1.72            0.94--3.12    0.08
  N2--N3/N0--N1    0.96            0.55--1.68   0.90   1.24            0.68--2.28    0.48
  Drinking         1.37            0.76--2.49   0.29   1.21            0.64--2.31    0.56
                                                                                      
  *Site*                                                                             
   Larynx          1.29            0.57--2.89   0.54   1.34            0.54--3.30    0.53
   Oral cavity     1.35            0.66--2.78   0.41   1.65            0.75--3.60    0.21
   Hypopharynx     1.73            0.66--4.56   0.27   1.69            0.59-- 4.84   0.33
   Oropharynx      1 (Reference)                       1 (Reference)                  
                                                                                      
  *p16 Staining*                                                                     
   HN              0.092           0.01--0.71   0.02   0.10            0.01--0.78    0.03
   LS              0.475           0.24--0.95   0.03   0.37            0.18--0.75    0.01
   HC              1 (Reference)                       1 (Reference)                  
                                                                                      
  HPV positives    0.65            0.24--1.81   0.41   0.54            0.179--1.61   0.27

Abbreviations: CI=confidence interval; HC=high cytoplasmic, low nuclear staining; HN=high nuclear, high cytoplasmic staining; HR=hazard ratio; LS=low nuclear, low cytoplasmic staining; OS=overall survival; PFS=progression-free survival.
